Navigation Links
Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
Date:10/22/2007

LEXINGTON, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) today announced that David B. Sharrock has elected to retire from its board of directors.

"I want to thank David for the many contributions he has made to Indevus during his more than 12 years of service to the Company," said Glenn L. Cooper, M.D., chairman and chief executive officer of Indevus. "David has provided invaluable guidance to the Company as we have moved from a development-stage company toward a specialty pharmaceutical company with several marketed products. All of us at Indevus are grateful to David and we wish him the best."

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) XR and SANCTURA(R) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA, for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnerable programs. The most advanced compounds in development include, VALSTAR(R) for bladder cancer, NEBIDO(R) for male hypogonadism, PRO 2000 for the prevention of infection by HIV and other sexually-transmitted pathogens, and pagoclone for stuttering.

Forward Looking Statements

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and fi
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Marianjoy Rehabilitation Hospital ... and hand impairments by acquiring the Armeo®Spring arm ... network site. , Secured through grant support of ... treatment option for patients with upper extremity weakness ... one of just four Illinois providers offering treatment ...
(Date:5/1/2015)... leading North American IT solutions and managed services provider, announced ... Partner Summit Country awards. Cisco named Softchoice ... the Year for Canada during its ... Montreal . "We are thrilled to ... year,s conference," said David MacDonald , Softchoice,s President and ...
(Date:5/1/2015)... TRIANGLE PARK, N.C. , May 1, 2015  United ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer of ... company,s business at the Deutsche Bank 40 th Annual ... The presentation will take place on Wednesday, May ... accessed via a live webcast on the United Therapeutics website ...
(Date:4/30/2015)... 30, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... that it has commenced an underwritten public offering of ... the underwriters a 30-day option to purchase up to ... stock offered in the public offering. The offering is ... assurance as to whether or when the offering may ...
Breaking Biology Technology:Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2Softchoice recognized with two Country Awards at Cisco Partner Summit 2015 2BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3
... Ltd. has begun,the second stage of its FDA ... brain tumors using MR guided Focused Ultrasound,Surgery on ... study are to evaluate the safety of focused,ultrasound ... the effect of,the thermal ablation on the tumors. ...
... ST. JOSEPH, Mich., Sept. 25 GeneGo, Inc., ... Bristol-Myers Squibb,(NYSE: BMY ) has licensed access ... technology, research and development sites within,Bristol-Myers Squibb will ... and/or genomics data to address questions from both ...
... team including scientists from the London Centre for Nanotechnology ... the National Academy of Sciences (PNAS) demonstrating the dramatic ... importance of the work lies in establishing how a ... at particle accelerators and nuclear reactors can be ...
Cached Biology Technology:InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors 2InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors 3GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases 2Imaging quantum entanglement 2
(Date:4/17/2015)... , April 17, 2015 ... security concerns, and technological advancement to drive biometric ... until 2020   According to ... Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market ... projected to register growth at CAGR of over ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... 2015 At its 2015 ACMG Annual Clinical ... , the American College of Medical Genetics and Genomics ... its Board.  Members of the ACMG Board of Directors ... and advancing its policies and programs. ACMG is the ... "It,s an eventful time in medical genetics and genomics.  ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8
... Mother Nature by developing, for the first time, ... tiny, hair-like structures through which organisms derive smell, ... new material isn,t exactly like cilia, it responds ... to control it and opening unlimited possibilities for ...
... BOSTONDana-Farber Cancer Institute,s Belfer Institute of Applied ... and NYSE: SNY) announced today that they have ... to identify and validate novel oncology targets ... novel therapeutics agents directed to such targets and ...
... Edward Yu of Iowa State University and the Ames Laboratory ... metal toxins from bacteria, making them resistant to antibiotics. ... of the journal Nature . Yu an ... of biochemistry, biophysics and molecular biology and an associate of ...
Cached Biology News:Cilia revolution 2Dana-Farber and sanofi-aventis establish cancer research alliance 2Iowa State, Ames Lab researchers identify structure that allows bacteria to resist drugs 2
Mouse monoclonal antibody to FMN2 - formin 2...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
Rabbit polyclonal to SMARCA2 / BRM - ChIP Grade ( Abpromise for all tested applications). entrezGeneID: 6595 SwissProtID: P51531...
Determin interaction of your protein with Echelons lipids...
Biology Products: